GSK has agreed to pay $1.2 billion upfront to acquire rights to efimosfermin from Cambridge, Massachusetts-based Boston ...

Weight-loss drugs and bariatric surgery both have an impact on cancer risk. A new study breaks down the link and how GLP-1 ...